APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Insulin Glargine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Long-acting Insulin Glargine Market Analysis and Forecast 2026-2032

Report ID 174008820223 December 2025194 pages

Choose your research edition.

Industry ResearchLong-acting Insulin Glargine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Insulin Glargine Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Long-acting Insulin Glargine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Insulin Glargine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Insulin Glargine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Long-acting Insulin Glargine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Long-acting Insulin Glargine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Long-acting Insulin Glargine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Long-acting Insulin Glargine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Long-acting Insulin Glargine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Long-acting Insulin Glargine include Biocare, Biocon Biologics, Cipla, INFION PHARMA, KALBE PHARMA, Lupin Laboratories, Swixx Biopharma, Viatris and Wockhardt, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Long-acting Insulin Glargine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Long-acting Insulin Glargine, also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting Insulin Glargine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting Insulin Glargine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Long-acting Insulin Glargine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Long-acting Insulin Glargine sales, projected growth trends, production technology, application and end-user industry.

Long-acting Insulin Glargine Segment by Company

Biocare

Biocon Biologics

Cipla

INFION PHARMA

KALBE PHARMA

Lupin Laboratories

Swixx Biopharma

Viatris

Wockhardt

Gan & Lee

Eli Lilly & Co

Sanofi

Tonghua Dongbao

United Laboratories

Long-acting Insulin Glargine Segment by Type

Vial

Prefilled

Long-acting Insulin Glargine Segment by Application

Type 2 Diabetes

Type 1 Diabetes

Long-acting Insulin Glargine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Insulin Glargine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Insulin Glargine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Insulin Glargine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Long-acting Insulin Glargine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Long-acting Insulin Glargine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting Insulin Glargine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting Insulin Glargine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vial Major Manufacturers Table 3. Prefilled Major Manufacturers Table 4. Global Long-acting Insulin Glargine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Type 2 Diabetes Major Manufacturers Table 6. Type 1 Diabetes Major Manufacturers Table 7. Long-acting Insulin Glargine Industry Trends Table 8. Long-acting Insulin Glargine Industry Drivers Table 9. Long-acting Insulin Glargine Industry Opportunities and Challenges Table 10. Long-acting Insulin Glargine Industry Restraints Table 11. Global Long-acting Insulin Glargine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Long-acting Insulin Glargine Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Long-acting Insulin Glargine Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Long-acting Insulin Glargine Revenue Market Share by Region (2021-2026) Table 15. Global Long-acting Insulin Glargine Revenue Market Share by Region (2027-2032) Table 16. Global Long-acting Insulin Glargine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 17. Global Long-acting Insulin Glargine Sales by Region (2021-2026) & (k units) Table 18. Global Long-acting Insulin Glargine Sales by Region (2027-2032) & (k units) Table 19. Global Long-acting Insulin Glargine Sales Market Share by Region (2021-2026) Table 20. Global Long-acting Insulin Glargine Sales Market Share by Region (2027-2032) Table 21. Global Long-acting Insulin Glargine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Long-acting Insulin Glargine Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Long-acting Insulin Glargine Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Long-acting Insulin Glargine Sales Market Share by Manufacturers (2021-2026) Table 25. Global Long-acting Insulin Glargine Sales Price (USD/unit) of Manufacturers (2021-2026) Table 26. Global Long-acting Insulin Glargine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Long-acting Insulin Glargine Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Long-acting Insulin Glargine Manufacturers, Product Type & Application Table 29. Global Long-acting Insulin Glargine Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Long-acting Insulin Glargine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Long-acting Insulin Glargine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Long-acting Insulin Glargine Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Long-acting Insulin Glargine Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Long-acting Insulin Glargine Revenue Market Share by Type (2021-2026) Table 36. Global Long-acting Insulin Glargine Revenue Market Share by Type (2027-2032) Table 37. Global Long-acting Insulin Glargine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 38. Global Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 39. Global Long-acting Insulin Glargine Sales by Type (2027-2032) & (k units) Table 40. Global Long-acting Insulin Glargine Sales Market Share by Type (2021-2026) Table 41. Global Long-acting Insulin Glargine Sales Market Share by Type (2027-2032) Table 42. Global Long-acting Insulin Glargine Price by Type (2021-2026) & (USD/unit) Table 43. Global Long-acting Insulin Glargine Price by Type (2027-2032) & (USD/unit) Table 44. Global Long-acting Insulin Glargine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Long-acting Insulin Glargine Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Long-acting Insulin Glargine Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Long-acting Insulin Glargine Revenue Market Share by Application (2021-2026) Table 48. Global Long-acting Insulin Glargine Revenue Market Share by Application (2027-2032) Table 49. Global Long-acting Insulin Glargine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 50. Global Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 51. Global Long-acting Insulin Glargine Sales by Application (2027-2032) & (k units) Table 52. Global Long-acting Insulin Glargine Sales Market Share by Application (2021-2026) Table 53. Global Long-acting Insulin Glargine Sales Market Share by Application (2027-2032) Table 54. Global Long-acting Insulin Glargine Price by Application (2021-2026) & (USD/unit) Table 55. Global Long-acting Insulin Glargine Price by Application (2027-2032) & (USD/unit) Table 56. Biocare Company Information Table 57. Biocare Business Overview Table 58. Biocare Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 59. Biocare Long-acting Insulin Glargine Product Portfolio Table 60. Biocare Recent Development Table 61. Biocon Biologics Company Information Table 62. Biocon Biologics Business Overview Table 63. Biocon Biologics Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 64. Biocon Biologics Long-acting Insulin Glargine Product Portfolio Table 65. Biocon Biologics Recent Development Table 66. Cipla Company Information Table 67. Cipla Business Overview Table 68. Cipla Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 69. Cipla Long-acting Insulin Glargine Product Portfolio Table 70. Cipla Recent Development Table 71. INFION PHARMA Company Information Table 72. INFION PHARMA Business Overview Table 73. INFION PHARMA Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. INFION PHARMA Long-acting Insulin Glargine Product Portfolio Table 75. INFION PHARMA Recent Development Table 76. KALBE PHARMA Company Information Table 77. KALBE PHARMA Business Overview Table 78. KALBE PHARMA Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. KALBE PHARMA Long-acting Insulin Glargine Product Portfolio Table 80. KALBE PHARMA Recent Development Table 81. Lupin Laboratories Company Information Table 82. Lupin Laboratories Business Overview Table 83. Lupin Laboratories Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Lupin Laboratories Long-acting Insulin Glargine Product Portfolio Table 85. Lupin Laboratories Recent Development Table 86. Swixx Biopharma Company Information Table 87. Swixx Biopharma Business Overview Table 88. Swixx Biopharma Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Swixx Biopharma Long-acting Insulin Glargine Product Portfolio Table 90. Swixx Biopharma Recent Development Table 91. Viatris Company Information Table 92. Viatris Business Overview Table 93. Viatris Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Viatris Long-acting Insulin Glargine Product Portfolio Table 95. Viatris Recent Development Table 96. Wockhardt Company Information Table 97. Wockhardt Business Overview Table 98. Wockhardt Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Wockhardt Long-acting Insulin Glargine Product Portfolio Table 100. Wockhardt Recent Development Table 101. Gan & Lee Company Information Table 102. Gan & Lee Business Overview Table 103. Gan & Lee Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Gan & Lee Long-acting Insulin Glargine Product Portfolio Table 105. Gan & Lee Recent Development Table 106. Eli Lilly & Co Company Information Table 107. Eli Lilly & Co Business Overview Table 108. Eli Lilly & Co Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Eli Lilly & Co Long-acting Insulin Glargine Product Portfolio Table 110. Eli Lilly & Co Recent Development Table 111. Sanofi Company Information Table 112. Sanofi Business Overview Table 113. Sanofi Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Sanofi Long-acting Insulin Glargine Product Portfolio Table 115. Sanofi Recent Development Table 116. Tonghua Dongbao Company Information Table 117. Tonghua Dongbao Business Overview Table 118. Tonghua Dongbao Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Tonghua Dongbao Long-acting Insulin Glargine Product Portfolio Table 120. Tonghua Dongbao Recent Development Table 121. United Laboratories Company Information Table 122. United Laboratories Business Overview Table 123. United Laboratories Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. United Laboratories Long-acting Insulin Glargine Product Portfolio Table 125. United Laboratories Recent Development Table 126. North America Long-acting Insulin Glargine Revenue by Type (2021-2026) & (US$ Million) Table 127. North America Long-acting Insulin Glargine Revenue by Type (2027-2032) & (US$ Million) Table 128. North America Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 129. North America Long-acting Insulin Glargine Sales by Type (2027-2032) & (k units) Table 130. North America Long-acting Insulin Glargine Sales Price by Type (2021-2026) & (USD/unit) Table 131. North America Long-acting Insulin Glargine Sales Price by Type (2027-2032) & (USD/unit) Table 132. North America Long-acting Insulin Glargine Revenue by Application (2021-2026) & (US$ Million) Table 133. North America Long-acting Insulin Glargine Revenue by Application (2027-2032) & (US$ Million) Table 134. North America Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 135. North America Long-acting Insulin Glargine Sales by Application (2027-2032) & (k units) Table 136. North America Long-acting Insulin Glargine Sales Price by Application (2021-2026) & (USD/unit) Table 137. North America Long-acting Insulin Glargine Sales Price by Application (2027-2032) & (USD/unit) Table 138. North America Long-acting Insulin Glargine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. North America Long-acting Insulin Glargine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 140. North America Long-acting Insulin Glargine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 141. North America Long-acting Insulin Glargine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 142. North America Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 143. North America Long-acting Insulin Glargine Sales by Country (2027-2032) & (k units) Table 144. North America Long-acting Insulin Glargine Sales Price by Country (2021-2026) & (USD/unit) Table 145. North America Long-acting Insulin Glargine Sales Price by Country (2027-2032) & (USD/unit) Table 146. United States Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 147. Canada Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 148. Mexico Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 149. Europe Long-acting Insulin Glargine Revenue by Type (2021-2026) & (US$ Million) Table 150. Europe Long-acting Insulin Glargine Revenue by Type (2027-2032) & (US$ Million) Table 151. Europe Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 152. Europe Long-acting Insulin Glargine Sales by Type (2027-2032) & (k units) Table 153. Europe Long-acting Insulin Glargine Sales Price by Type (2021-2026) & (USD/unit) Table 154. Europe Long-acting Insulin Glargine Sales Price by Type (2027-2032) & (USD/unit) Table 155. Europe Long-acting Insulin Glargine Revenue by Application (2021-2026) & (US$ Million) Table 156. Europe Long-acting Insulin Glargine Revenue by Application (2027-2032) & (US$ Million) Table 157. Europe Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 158. Europe Long-acting Insulin Glargine Sales by Application (2027-2032) & (k units) Table 159. Europe Long-acting Insulin Glargine Sales Price by Application (2021-2026) & (USD/unit) Table 160. Europe Long-acting Insulin Glargine Sales Price by Application (2027-2032) & (USD/unit) Table 161. Europe Long-acting Insulin Glargine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Europe Long-acting Insulin Glargine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. Europe Long-acting Insulin Glargine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. Europe Long-acting Insulin Glargine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 165. Europe Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 166. Europe Long-acting Insulin Glargine Sales by Country (2027-2032) & (k units) Table 167. Europe Long-acting Insulin Glargine Sales Price by Country (2021-2026) & (USD/unit) Table 168. Europe Long-acting Insulin Glargine Sales Price by Country (2027-2032) & (USD/unit) Table 169. Germany Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 170. France Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 171. U.K. Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 172. Italy Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 173. Russia Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 174. Spain Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 175. Netherlands Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 176. Switzerland Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 177. Sweden Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 178. Poland Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 179. China Long-acting Insulin Glargine Revenue by Type (2021-2026) & (US$ Million) Table 180. China Long-acting Insulin Glargine Revenue by Type (2027-2032) & (US$ Million) Table 181. China Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 182. China Long-acting Insulin Glargine Sales by Type (2027-2032) & (k units) Table 183. China Long-acting Insulin Glargine Sales Price by Type (2021-2026) & (USD/unit) Table 184. China Long-acting Insulin Glargine Sales Price by Type (2027-2032) & (USD/unit) Table 185. China Long-acting Insulin Glargine Revenue by Application (2021-2026) & (US$ Million) Table 186. China Long-acting Insulin Glargine Revenue by Application (2027-2032) & (US$ Million) Table 187. China Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 188. China Long-acting Insulin Glargine Sales by Application (2027-2032) & (k units) Table 189. China Long-acting Insulin Glargine Sales Price by Application (2021-2026) & (USD/unit) Table 190. China Long-acting Insulin Glargine Sales Price by Application (2027-2032) & (USD/unit) Table 191. Asia Long-acting Insulin Glargine Revenue by Type (2021-2026) & (US$ Million) Table 192. Asia Long-acting Insulin Glargine Revenue by Type (2027-2032) & (US$ Million) Table 193. Asia Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 194. Asia Long-acting Insulin Glargine Sales by Type (2027-2032) & (k units) Table 195. Asia Long-acting Insulin Glargine Sales Price by Type (2021-2026) & (USD/unit) Table 196. Asia Long-acting Insulin Glargine Sales Price by Type (2027-2032) & (USD/unit) Table 197. Asia Long-acting Insulin Glargine Revenue by Application (2021-2026) & (US$ Million) Table 198. Asia Long-acting Insulin Glargine Revenue by Application (2027-2032) & (US$ Million) Table 199. Asia Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 200. Asia Long-acting Insulin Glargine Sales by Application (2027-2032) & (k units) Table 201. Asia Long-acting Insulin Glargine Sales Price by Application (2021-2026) & (USD/unit) Table 202. Asia Long-acting Insulin Glargine Sales Price by Application (2027-2032) & (USD/unit) Table 203. Asia Long-acting Insulin Glargine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 204. Asia Long-acting Insulin Glargine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 205. Asia Long-acting Insulin Glargine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 206. Asia Long-acting Insulin Glargine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 207. Asia Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 208. Asia Long-acting Insulin Glargine Sales by Country (2027-2032) & (k units) Table 209. Asia Long-acting Insulin Glargine Sales Price by Country (2021-2026) & (USD/unit) Table 210. Asia Long-acting Insulin Glargine Sales Price by Country (2027-2032) & (USD/unit) Table 211. Japan Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 212. South Korea Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 213. India Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 214. Australia Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 215. Taiwan Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 216. Southeast Asia Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 217. SAMEA Long-acting Insulin Glargine Revenue by Type (2021-2026) & (US$ Million) Table 218. SAMEA Long-acting Insulin Glargine Revenue by Type (2027-2032) & (US$ Million) Table 219. SAMEA Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 220. SAMEA Long-acting Insulin Glargine Sales by Type (2027-2032) & (k units) Table 221. SAMEA Long-acting Insulin Glargine Sales Price by Type (2021-2026) & (USD/unit) Table 222. SAMEA Long-acting Insulin Glargine Sales Price by Type (2027-2032) & (USD/unit) Table 223. SAMEA Long-acting Insulin Glargine Revenue by Application (2021-2026) & (US$ Million) Table 224. SAMEA Long-acting Insulin Glargine Revenue by Application (2027-2032) & (US$ Million) Table 225. SAMEA Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 226. SAMEA Long-acting Insulin Glargine Sales by Application (2027-2032) & (k units) Table 227. SAMEA Long-acting Insulin Glargine Sales Price by Application (2021-2026) & (USD/unit) Table 228. SAMEA Long-acting Insulin Glargine Sales Price by Application (2027-2032) & (USD/unit) Table 229. SAMEA Long-acting Insulin Glargine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 230. SAMEA Long-acting Insulin Glargine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 231. SAMEA Long-acting Insulin Glargine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 232. SAMEA Long-acting Insulin Glargine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 233. SAMEA Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 234. SAMEA Long-acting Insulin Glargine Sales by Country (2027-2032) & (k units) Table 235. SAMEA Long-acting Insulin Glargine Sales Price by Country (2021-2026) & (USD/unit) Table 236. SAMEA Long-acting Insulin Glargine Sales Price by Country (2027-2032) & (USD/unit) Table 237. Brazil Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 238. Argentina Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 239. Chile Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 240. Colombia Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 241. Peru Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 242. Saudi Arabia Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 243. Israel Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 244. UAE Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 245. Turkey Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 246. Iran Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 247. Egypt Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Table 248. Key Raw Materials Table 249. Raw Materials Key Suppliers Table 250. Long-acting Insulin Glargine Distributors List Table 251. Long-acting Insulin Glargine Customers List Table 252. Research Programs/Design for This Report Table 253. Authors List of This Report Table 254. Secondary Sources Table 255. Primary Sources List of Figures Figure 1. Long-acting Insulin Glargine Image Figure 2. Global Long-acting Insulin Glargine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Insulin Glargine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vial Image Figure 5. Prefilled Image Figure 6. Global Long-acting Insulin Glargine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Long-acting Insulin Glargine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Type 2 Diabetes Image Figure 9. Type 1 Diabetes Image Figure 10. Global Long-acting Insulin Glargine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Figure 12. Global Long-acting Insulin Glargine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Long-acting Insulin Glargine Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Long-acting Insulin Glargine Revenue Market Share by Region (2021-2032) Figure 15. Global Long-acting Insulin Glargine Sales (2021-2032) & (k units) Figure 16. Global Long-acting Insulin Glargine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 17. Global Long-acting Insulin Glargine Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Long-acting Insulin Glargine Sales YoY (2021-2032) & (k units) Figure 19. Europe Long-acting Insulin Glargine Sales YoY (2021-2032) & (k units) Figure 20. China Long-acting Insulin Glargine Sales YoY (2021-2032) & (k units) Figure 21. Asia (Excluding China) Long-acting Insulin Glargine Sales YoY (2021-2032) & (k units) Figure 22. South America, Middle East and Africa Long-acting Insulin Glargine Sales YoY (2021-2032) & (k units) Figure 23. Global Long-acting Insulin Glargine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Long-acting Insulin Glargine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Long-acting Insulin Glargine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Long-acting Insulin Glargine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Long-acting Insulin Glargine Revenue Market Share by Type (2021-2032) Figure 29. Global Long-acting Insulin Glargine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 30. Global Long-acting Insulin Glargine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Long-acting Insulin Glargine Sales Market Share by Type (2021-2032) Figure 32. Global Long-acting Insulin Glargine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Long-acting Insulin Glargine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Long-acting Insulin Glargine Revenue Market Share by Application (2021-2032) Figure 35. Global Long-acting Insulin Glargine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Long-acting Insulin Glargine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Long-acting Insulin Glargine Sales Market Share by Application (2021-2032) Figure 38. North America Long-acting Insulin Glargine Revenue Share by Type (2021-2032) Figure 39. North America Long-acting Insulin Glargine Sales Share by Type (2021-2032) Figure 40. North America Long-acting Insulin Glargine Revenue Share by Application (2021-2032) Figure 41. North America Long-acting Insulin Glargine Sales Share by Application (2021-2032) Figure 42. North America Long-acting Insulin Glargine Revenue Share by Country (2021-2032) Figure 43. North America Long-acting Insulin Glargine Sales Share by Country (2021-2032) Figure 44. Europe Long-acting Insulin Glargine Revenue Share by Type (2021-2032) Figure 45. Europe Long-acting Insulin Glargine Sales Share by Type (2021-2032) Figure 46. Europe Long-acting Insulin Glargine Revenue Share by Application (2021-2032) Figure 47. Europe Long-acting Insulin Glargine Sales Share by Application (2021-2032) Figure 48. Europe Long-acting Insulin Glargine Revenue Share by Country (2021-2032) Figure 49. Europe Long-acting Insulin Glargine Sales Share by Country (2021-2032) Figure 50. China Long-acting Insulin Glargine Revenue Share by Type (2021-2032) Figure 51. China Long-acting Insulin Glargine Sales Share by Type (2021-2032) Figure 52. China Long-acting Insulin Glargine Revenue Share by Application (2021-2032) Figure 53. China Long-acting Insulin Glargine Sales Share by Application (2021-2032) Figure 54. Asia Long-acting Insulin Glargine Revenue Share by Type (2021-2032) Figure 55. Asia Long-acting Insulin Glargine Sales Share by Type (2021-2032) Figure 56. Asia Long-acting Insulin Glargine Revenue Share by Application (2021-2032) Figure 57. Asia Long-acting Insulin Glargine Sales Share by Application (2021-2032) Figure 58. Asia Long-acting Insulin Glargine Revenue Share by Country (2021-2032) Figure 59. Asia Long-acting Insulin Glargine Sales Share by Country (2021-2032) Figure 60. SAMEA Long-acting Insulin Glargine Revenue Share by Type (2021-2032) Figure 61. SAMEA Long-acting Insulin Glargine Sales Share by Type (2021-2032) Figure 62. SAMEA Long-acting Insulin Glargine Revenue Share by Application (2021-2032) Figure 63. SAMEA Long-acting Insulin Glargine Sales Share by Application (2021-2032) Figure 64. SAMEA Long-acting Insulin Glargine Revenue Share by Country (2021-2032) Figure 65. SAMEA Long-acting Insulin Glargine Sales Share by Country (2021-2032) Figure 66. Long-acting Insulin Glargine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Long-acting Insulin Glargine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Vial
  • Prefilled
Applications
  • Type 2 Diabetes
  • Type 1 Diabetes
Companies covered
  • Biocare
  • Biocon Biologics
  • Cipla
  • INFION PHARMA
  • KALBE PHARMA
  • Lupin Laboratories
  • Swixx Biopharma
  • Viatris
  • Wockhardt
  • Gan & Lee
  • Eli Lilly & Co
  • Sanofi
  • Tonghua Dongbao
  • United Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Long-acting Insulin Glargine Market by Type
  3. 1.2.1 Global Long-acting Insulin Glargine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vial
  5. 1.2.3 Prefilled
  6. 1.3 Long-acting Insulin Glargine Market by Application
  7. 1.3.1 Global Long-acting Insulin Glargine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Type 2 Diabetes
  9. 1.3.3 Type 1 Diabetes
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Long-acting Insulin Glargine Market Dynamics
  1. 2.1 Long-acting Insulin Glargine Industry Trends
  2. 2.2 Long-acting Insulin Glargine Industry Drivers
  3. 2.3 Long-acting Insulin Glargine Industry Opportunities and Challenges
  4. 2.4 Long-acting Insulin Glargine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Long-acting Insulin Glargine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Long-acting Insulin Glargine Revenue by Region
  3. 3.2.1 Global Long-acting Insulin Glargine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Long-acting Insulin Glargine Revenue by Region (2021-2026)
  5. 3.2.3 Global Long-acting Insulin Glargine Revenue by Region (2027-2032)
  6. 3.2.4 Global Long-acting Insulin Glargine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Long-acting Insulin Glargine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Long-acting Insulin Glargine Sales by Region
  9. 3.4.1 Global Long-acting Insulin Glargine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Long-acting Insulin Glargine Sales by Region (2021-2026)
  11. 3.4.3 Global Long-acting Insulin Glargine Sales by Region (2027-2032)
  12. 3.4.4 Global Long-acting Insulin Glargine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Long-acting Insulin Glargine Revenue by Manufacturers
  2. 4.1.1 Global Long-acting Insulin Glargine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Long-acting Insulin Glargine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Long-acting Insulin Glargine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Long-acting Insulin Glargine Sales by Manufacturers
  6. 4.2.1 Global Long-acting Insulin Glargine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Long-acting Insulin Glargine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Long-acting Insulin Glargine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Long-acting Insulin Glargine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Long-acting Insulin Glargine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Long-acting Insulin Glargine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Long-acting Insulin Glargine Manufacturers, Product Type & Application
  13. 4.7 Global Long-acting Insulin Glargine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Long-acting Insulin Glargine Market CR5 and HHI
  16. 4.8.2 2025 Long-acting Insulin Glargine Tier 1, Tier 2, and Tier 3
5 Long-acting Insulin Glargine Market by Type
  1. 5.1 Global Long-acting Insulin Glargine Revenue by Type
  2. 5.1.1 Global Long-acting Insulin Glargine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Long-acting Insulin Glargine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Long-acting Insulin Glargine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Long-acting Insulin Glargine Sales by Type
  6. 5.2.1 Global Long-acting Insulin Glargine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting Insulin Glargine Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Long-acting Insulin Glargine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Long-acting Insulin Glargine Price by Type
6 Long-acting Insulin Glargine Market by Application
  1. 6.1 Global Long-acting Insulin Glargine Revenue by Application
  2. 6.1.1 Global Long-acting Insulin Glargine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Long-acting Insulin Glargine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Long-acting Insulin Glargine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Long-acting Insulin Glargine Sales by Application
  6. 6.2.1 Global Long-acting Insulin Glargine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Long-acting Insulin Glargine Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Long-acting Insulin Glargine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Long-acting Insulin Glargine Price by Application
7 Company Profiles
  1. 7.1 Biocare
  2. 7.1.1 Biocare Company Information
  3. 7.1.2 Biocare Business Overview
  4. 7.1.3 Biocare Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Biocare Long-acting Insulin Glargine Product Portfolio
  6. 7.1.5 Biocare Recent Developments
  7. 7.2 Biocon Biologics
  8. 7.2.1 Biocon Biologics Company Information
  9. 7.2.2 Biocon Biologics Business Overview
  10. 7.2.3 Biocon Biologics Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Biocon Biologics Long-acting Insulin Glargine Product Portfolio
  12. 7.2.5 Biocon Biologics Recent Developments
  13. 7.3 Cipla
  14. 7.3.1 Cipla Company Information
  15. 7.3.2 Cipla Business Overview
  16. 7.3.3 Cipla Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Cipla Long-acting Insulin Glargine Product Portfolio
  18. 7.3.5 Cipla Recent Developments
  19. 7.4 INFION PHARMA
  20. 7.4.1 INFION PHARMA Company Information
  21. 7.4.2 INFION PHARMA Business Overview
  22. 7.4.3 INFION PHARMA Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 INFION PHARMA Long-acting Insulin Glargine Product Portfolio
  24. 7.4.5 INFION PHARMA Recent Developments
  25. 7.5 KALBE PHARMA
  26. 7.5.1 KALBE PHARMA Company Information
  27. 7.5.2 KALBE PHARMA Business Overview
  28. 7.5.3 KALBE PHARMA Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 KALBE PHARMA Long-acting Insulin Glargine Product Portfolio
  30. 7.5.5 KALBE PHARMA Recent Developments
  31. 7.6 Lupin Laboratories
  32. 7.6.1 Lupin Laboratories Company Information
  33. 7.6.2 Lupin Laboratories Business Overview
  34. 7.6.3 Lupin Laboratories Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Lupin Laboratories Long-acting Insulin Glargine Product Portfolio
  36. 7.6.5 Lupin Laboratories Recent Developments
  37. 7.7 Swixx Biopharma
  38. 7.7.1 Swixx Biopharma Company Information
  39. 7.7.2 Swixx Biopharma Business Overview
  40. 7.7.3 Swixx Biopharma Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Swixx Biopharma Long-acting Insulin Glargine Product Portfolio
  42. 7.7.5 Swixx Biopharma Recent Developments
  43. 7.8 Viatris
  44. 7.8.1 Viatris Company Information
  45. 7.8.2 Viatris Business Overview
  46. 7.8.3 Viatris Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Viatris Long-acting Insulin Glargine Product Portfolio
  48. 7.8.5 Viatris Recent Developments
  49. 7.9 Wockhardt
  50. 7.9.1 Wockhardt Company Information
  51. 7.9.2 Wockhardt Business Overview
  52. 7.9.3 Wockhardt Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Wockhardt Long-acting Insulin Glargine Product Portfolio
  54. 7.9.5 Wockhardt Recent Developments
  55. 7.10 Gan & Lee
  56. 7.10.1 Gan & Lee Company Information
  57. 7.10.2 Gan & Lee Business Overview
  58. 7.10.3 Gan & Lee Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Gan & Lee Long-acting Insulin Glargine Product Portfolio
  60. 7.10.5 Gan & Lee Recent Developments
  61. 7.11 Eli Lilly & Co
  62. 7.11.1 Eli Lilly & Co Company Information
  63. 7.11.2 Eli Lilly & Co Business Overview
  64. 7.11.3 Eli Lilly & Co Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Eli Lilly & Co Long-acting Insulin Glargine Product Portfolio
  66. 7.11.5 Eli Lilly & Co Recent Developments
  67. 7.12 Sanofi
  68. 7.12.1 Sanofi Company Information
  69. 7.12.2 Sanofi Business Overview
  70. 7.12.3 Sanofi Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Sanofi Long-acting Insulin Glargine Product Portfolio
  72. 7.12.5 Sanofi Recent Developments
  73. 7.13 Tonghua Dongbao
  74. 7.13.1 Tonghua Dongbao Company Information
  75. 7.13.2 Tonghua Dongbao Business Overview
  76. 7.13.3 Tonghua Dongbao Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Tonghua Dongbao Long-acting Insulin Glargine Product Portfolio
  78. 7.13.5 Tonghua Dongbao Recent Developments
  79. 7.14 United Laboratories
  80. 7.14.1 United Laboratories Company Information
  81. 7.14.2 United Laboratories Business Overview
  82. 7.14.3 United Laboratories Long-acting Insulin Glargine Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 United Laboratories Long-acting Insulin Glargine Product Portfolio
  84. 7.14.5 United Laboratories Recent Developments
8 North America
  1. 8.1 North America Long-acting Insulin Glargine Market Size by Type
  2. 8.1.1 North America Long-acting Insulin Glargine Revenue by Type (2021-2032)
  3. 8.1.2 North America Long-acting Insulin Glargine Sales by Type (2021-2032)
  4. 8.1.3 North America Long-acting Insulin Glargine Price by Type (2021-2032)
  5. 8.2 North America Long-acting Insulin Glargine Market Size by Application
  6. 8.2.1 North America Long-acting Insulin Glargine Revenue by Application (2021-2032)
  7. 8.2.2 North America Long-acting Insulin Glargine Sales by Application (2021-2032)
  8. 8.2.3 North America Long-acting Insulin Glargine Price by Application (2021-2032)
  9. 8.3 North America Long-acting Insulin Glargine Market Size by Country
  10. 8.3.1 North America Long-acting Insulin Glargine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Long-acting Insulin Glargine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Long-acting Insulin Glargine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Long-acting Insulin Glargine Market Size by Type
  2. 9.1.1 Europe Long-acting Insulin Glargine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Long-acting Insulin Glargine Sales by Type (2021-2032)
  4. 9.1.3 Europe Long-acting Insulin Glargine Price by Type (2021-2032)
  5. 9.2 Europe Long-acting Insulin Glargine Market Size by Application
  6. 9.2.1 Europe Long-acting Insulin Glargine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Long-acting Insulin Glargine Sales by Application (2021-2032)
  8. 9.2.3 Europe Long-acting Insulin Glargine Price by Application (2021-2032)
  9. 9.3 Europe Long-acting Insulin Glargine Market Size by Country
  10. 9.3.1 Europe Long-acting Insulin Glargine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Long-acting Insulin Glargine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Long-acting Insulin Glargine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Long-acting Insulin Glargine Market Size by Type
  2. 10.1.1 China Long-acting Insulin Glargine Revenue by Type (2021-2032)
  3. 10.1.2 China Long-acting Insulin Glargine Sales by Type (2021-2032)
  4. 10.1.3 China Long-acting Insulin Glargine Price by Type (2021-2032)
  5. 10.2 China Long-acting Insulin Glargine Market Size by Application
  6. 10.2.1 China Long-acting Insulin Glargine Revenue by Application (2021-2032)
  7. 10.2.2 China Long-acting Insulin Glargine Sales by Application (2021-2032)
  8. 10.2.3 China Long-acting Insulin Glargine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Long-acting Insulin Glargine Market Size by Type
  2. 11.1.1 Asia Long-acting Insulin Glargine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Long-acting Insulin Glargine Sales by Type (2021-2032)
  4. 11.1.3 Asia Long-acting Insulin Glargine Price by Type (2021-2032)
  5. 11.2 Asia Long-acting Insulin Glargine Market Size by Application
  6. 11.2.1 Asia Long-acting Insulin Glargine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Long-acting Insulin Glargine Sales by Application (2021-2032)
  8. 11.2.3 Asia Long-acting Insulin Glargine Price by Application (2021-2032)
  9. 11.3 Asia Long-acting Insulin Glargine Market Size by Country
  10. 11.3.1 Asia Long-acting Insulin Glargine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Long-acting Insulin Glargine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Long-acting Insulin Glargine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Long-acting Insulin Glargine Market Size by Type
  2. 12.1.1 SAMEA Long-acting Insulin Glargine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Long-acting Insulin Glargine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Long-acting Insulin Glargine Price by Type (2021-2032)
  5. 12.2 SAMEA Long-acting Insulin Glargine Market Size by Application
  6. 12.2.1 SAMEA Long-acting Insulin Glargine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Long-acting Insulin Glargine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Long-acting Insulin Glargine Price by Application (2021-2032)
  9. 12.3 SAMEA Long-acting Insulin Glargine Market Size by Country
  10. 12.3.1 SAMEA Long-acting Insulin Glargine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Long-acting Insulin Glargine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Long-acting Insulin Glargine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Long-acting Insulin Glargine Value Chain Analysis
  2. 13.1.1 Long-acting Insulin Glargine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Long-acting Insulin Glargine Production Mode & Process
  6. 13.2 Long-acting Insulin Glargine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Long-acting Insulin Glargine Distributors
  9. 13.2.3 Long-acting Insulin Glargine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst